18 Jan Anocca
Mark Farmery, Ph.D., Chief Development Officer
April 29 | 2:00pm | Salone dei Cavalieri, Section 1
Södertälje, Sweden
(Private)
Anocca is a clinical-stage biopharmaceutical company pioneering the development of next-generation T-cell receptor-engineered T cell (TCR-T) therapies to transform the treatment of solid tumor cancers. Anocca’s platform and product library unlocks the hurdles to cost-effective, industrial-scale development and deployment of personalized cell therapies, resulting in the largest pipeline of targeted TCR-T therapies in the world. Proprietary discovery technologies using programmable human cells and AI-acceleration, non-viral gene editing, and in-house GMP manufacturing give Anocca end-to-end control from disease gene-of-interest to developing and manufacturing products and executing clinical trials. The platform is designed for rapid iteration and lower per-asset development costs. The company’s pipeline includes 40+ assets covering high value shared cancer targets including dysregulated genes, driver mutations, and viral oncoproteins. Anocca’s lead assets are being evaluated in VIDAR-1, a phase I/II multi-site/product European umbrella clinical trial targeting KRAS oncogenic driver mutations in pancreatic ductal adenocarcinoma.